ArticleFrontiers in psychiatry2022
Peripheral non-enzymatic antioxidants as biomarkers for mood disorders: Evidence from a machine learning prediction model.
Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Clinical Characteristics and Blood-Based Inflammatory Indices of Psychiatric Hospitalizations Among Children with Autism in China: A Retrospective Electronic Medical Records Study.Brain sciences · 2026Article
- Peripheral biochemical parameters for discrimination between bipolar disorder and major depressive disorder in female patients of reproductive age: a CRP-stratified exploratory study.BMC psychiatry · 2026Article
- The nonenzymatic antioxidant profile as a biomarker for adolescent mood disorders: Cross-sectional and longitudinal analyses.The Journal of international medical research · 2026Article
- Development and external validation of a diagnostic model for differentiating major depressive disorder from bipolar disorder.BMC psychiatry · 2026Article
- Association Between Triglyceride-Glucose Index and Hyperuricemia in Hospitalized Patients with Depression: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2026Article
- Clinical Utility of Peripheral Non-Enzymatic Antioxidants in Differentiating Major Depressive Disorder from Bipolar Disorder: Associations with Antioxidant Levels, Hospitalization Outcomes, and Antidepressant Efficacy.Neuropsychiatric disease and treatment · 2026Article
- The future of diagnosis in mental health: Promises and challenges of biomarkers to identify reliable and highly predictive biosignatures of affective disorders.European psychiatry : the journal of the Association of European Psychiatrists · 2025Review
- Rapid identification of early renal damage in asymptomatic hyperuricemia patients based on urine Raman spectroscopy and bioinformatics analysis.Frontiers in chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress is related to the pathogenesis of mood disorders, and the level of oxidative stress may differ between bipolar disorder (BD) and major depressive disorder (MDD). This study aimed to detect the differences in non-enzymatic antioxidant levels between BD and MDD and assess the predictive values of non-enzymatic antioxidants in mood disorders by applying a machine learning model. Methods: Peripheral uric acid (UA), albumin (ALB), and total bilirubin (TBIL) were measured in 1,188 participants (discover cohort: 157 with BD and 544 with MDD; validation cohort: 119 with BD and 95 with MDD; 273 healthy controls). An extreme gradient boosting (XGBoost) model and a logistic regression model were used to assess the predictive effect. Results: All three indices differed between patients with mood disorders and healthy controls; in addition, the levels of UA in patients with BD were higher than those of patients with MDD. After treatment, UA levels increased in the MDD group, while they decreased in the BD group. Finally, we entered age, sex, UA, ALB, and TBIL into the XGBoost model. The area under the curve (AUC) of the XGBoost model for distinguishing between BD and MDD reached 0.849 (accuracy = 0.808, 95% CI = 0.719-0.878) and for distinguishing between BD with depression episode (BD-D) and MDD was 0.899 (accuracy = 0.891, 95% CI = 0.856-0.919). The models were validated in the validation cohort. The most important feature distinguishing between BD and MDD was UA. Conclusion: Peripheral non-enzymatic antioxidants, especially the UA, might be a potential biomarker capable of distinguishing between BD and MDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.